Intravenous ketamine therapy in a patient with a treatment-resistant major depression
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recently, reports from North America have indicated that the intravenous infusion of ketamine hydrochloride (an N-methyl-d-aspartate receptor antagonist) results in a sudden and robust improvement of depression symptoms. OBJECTIVE: To corroborate antidepressant effectiveness of IV ketamine in a patient with a co-occurring substance use disorder for the first time in a European clinical setting. DESIGN: Open label trial Methods: A 55-year-old male subject with a treatment-resistant major depression and a co-occurring alcohol and benzodiazepine dependence received an intravenous infusion of 0.5 mg/kg ketamine over a period of 50 minutes. Effects were assessed by means of a clinical interview, the 21-item Hamilton Depression Rating scale (HDRS), and the 21-item Beck Depression Inventory (BDI) at baseline, 1 hour, 1 day, 2 days, and 7 days after intervention. RESULTS: Following the administration of ketamine the subject experienced a significant improvement of his symptoms peaking on the 2nd day post infusion (HDRS from 36 to 16; -56.6%, BDI from 26 to 9; -65.4%). The subject first reported improvements 25 min. into the infusion and continued to describe positive effects throughout the subsequent 7 days. CONCLUSION: Ketamine not only seems to have strong antidepressant effects but also to act very swiftly. These actions were unaffected by an alcohol or benzodiazpine dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Cited by
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Ketamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
“One exception is a case of an MDD patient with polysubstance dependence (16,17).”
BackgroundThe use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Voleti, B., Navarria, A., Liu, R.-J., Banasr, M., Li, N., Terwilliger, R., Sanacora, G., Eid, T., Aghajanian, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.025 · Cited by 264
Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Stertz, L., Kapczinski, F., Gavioli, E. C., & Quevedo, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.01.004 · Cited by 237
“Other clinical studies replicated these findings and confirmed a rapid onset of action for ketamine on the treatment of major depression (Zarate et al., 2006; Liebrenz et al., 2007a,b).”
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care
Irwin, S. A., & Iglewicz, A. (2010) · Journal of Palliative Medicine · doi:10.1089/jpm.2010.9808 · Cited by 123
Ota, K. T., & Duman, R. S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.022 · Cited by 94
Neuroplasticity and the next wave of antidepressant strategies
Hayley, S., & Litteljohn, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00218 · Cited by 92
“Furthermore, the antidepressant effects following a single ketamine dose have been reported to persist for several days to even weeks (Correll and Futter, 2006; Liebrenz et al., 2007; Irwin and Iglewicz, 2010; Mathew et al., 2010).”
BackgroundNovel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
“…demonstrated to induce rapid antidepressant effects in subjects with depressive symptoms during pre- and post-operative states, as well as in MDD comorbid with pain syndrome and/or alcohol dependence (Goforth and Holsinger, 2007, Kudoh et al., 2002, Liebrenz et al., 2007, Ostroff et al., 2005).”
BackgroundOral ketamine for the treatment of pain and treatment-resistant depression
Schoevers, R. A., Chaves, T. V., Balukova, S. M., Rot, M. A. H., & Kortekaas, R. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.165498 · Cited by 81
Rapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
Iglewicz, A., Morrison, K., Nelesen, R. A., Zhan, T., Iglewicz, B., Fairman, N., Hirst, J. M., & Irwin, S. A. (2015) · Psychosomatics · doi:10.1016/j.psym.2014.05.005 · Cited by 60
The therapeutic potentials of Ayahuasca in the treatment of depression
Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_2 · Cited by 36
“For instance, studies conducted with ketamine, an NMDA antagonist, showed antidepressant effects after a single intravenous injection, which persisted significantly after 1 week (Liebrenz et al. 2007).”
BackgroundYang, C., Li, W.-Y., Yu, H.-Y., Gao, Z.-Q., Liu, X.-L., Zhou, Z.-Q., & Yang, J.-J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/175619 · Cited by 29
Réus, G. Z., Stringari, R. B., Rezin, G. T., Fraga, D. B., Daufenbach, J. F., Scaini, G., Benedet, J., Rochi, N., Streck, E. L., & Quevedo, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0718-2 · Cited by 23
“…have antidepressant effects in animal models of depression and in humans (Réus et al. 2010; Chourbaji et al. 2008; Feyissa et al. 2009; Garcia et al. 2008a, b; Phelps et al. 2009; Zarate and Manji 2008; Liebrenz et al. 2007; Ferguson and Shingleton 2007; Zarate et al. 2006; Berman et al. 2000).”
Background
Metadata
- Authors
- Liebrenz, M., Borgeat, A., & Leisinger, R.
- Venue
- Swiss Medical Weekly
- Publisher
- SMW Supporting Association
- Published
- 2007-04-21
- Volume
- 137
- Issue
- 1516
- Pages
- 234-236
- ISSN
- 0036-7672 (ISSN-L)
- 1424-3997
- OpenAlex
- W177130592
- Cited by
- 75
- References
- 2
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.